Investing.com - Concert Pharm reported on Monday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Concert Pharm announced earnings per share of $-0.580 on revenue of $8K. Analysts polled by Investing.com anticipated EPS of $-0.592 on revenue of $165K.
Concert Pharm shares are down 28% from the beginning of the year, still down 32.97% from its 52 week high of $7.37 set on August 11.
Concert Pharm shares lost 11.31% in intra-day trade following the report.
Concert Pharm follows other major Healthcare sector earnings this month
Concert Pharm's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar